Ana Gene Biotech
Mouse move on Image to zoom

ABL1 T315I MutIKitD

- Detection of ABL1 T315I mutation,
- Real-time PCR ARMS TaqMan Probe Technology,
- 24 Lyophilized Ready to use tubes,
- 24 Ready to use 2X tubes
- Highly Specific and Sensitive Detection Kit.

Catalog Number Description
- K2013: 2X version including 24 ready to use tubes contain 10 μl of qPCR mix 2X (two sets)
- K2013L: Lyophilized version including 24 ready to use lyophilized qPCR mix (two sets)
Lyophilized Version Price :
$100
Old Price :
$0
Amount
    •  
    •  Jan 2017
    •  
    •  2017

ABL1 T315I MutIKitD

The T315I mutation results in an threonine (T) to an isoleucine (I) amino acid substitution at position 315 in ABL1 kinase domain . Presence of T315I point mutations in BCR-ABL1 has been implicated as a mechanism of resistance to tyrosine-kinase inhibitors (TKIs) such as imatinib. the T315I mutated CML cohort has also demonstrated reduced efficacy and increased resistance with Dasatinib, Nilotinib and Bosutinib in preclinical and clinical studies. Phase I and II trials for Dasatinib (Soverini et al. 2007), Nilotinib (Lange et al. 2012), and Bosutinib (Cortes et al. 2011; Khoury et al. 2012) demonstrate lack of efficacy and resistance in this patient population. Soverini et al. (2011) made mutation-specific treatment decision recommendations that were adopted by NCCN (2012). For T315I, the recommendation was to pursue “hematopoietic stem cell transplantation (HSCT) or clinical trial” for patients with imatinib-resistant CML. In preclinical studies, T315I-mutated cell lines demonstrated decreased sensitivity to dasatinib, nilotinib, and bosutinib compared with CML cell lines wild type for mutations (Soverini et al. 2011).The mutation is detected in the Yellow channel and Internal control is detected in the FAM channel.

ABL1 T315I MutIKitD

- 24 Ready to use Lyophilized tubes (lyophilized Version kit)
- 24 Ready to use 2X tubes (2X Version kit)
- Positive Control
- Water Nuclease free
- Quick Protocol
- mini CD


ABL1 T315I MutIKitD

I. Sample Requirement
DNA from Peripheral blood: 0.5 - 1mL
DNA from Bone marrow: 0.5 - 1mL

II. Sensitivity
These reagents detect 10 copies of ABL1 T315I allele. Sensitivity of the assay was determined by serially
diluting the positive control of JAK2 V617F from 100 to 1 copy/PCR. Sensitivity of the assay was determined
as 10 copies/PCR. This means that there is 95% probability that 10 Copies/PCR will be detected.
III. Module Specificity
Test result will be positive, only to ABL1 T315I mutation. The primers and probes were checked for possible
homologies to all published sequences (Genbank) by BLAST analysis to avoid any homology with other
organisms.
IV. Reproducibility
Systematic kit production and strict quality control system eliminate batch variation of products. Thus, users
can get reproducible data even though they use different batch of product.
V. Quality Control
Functionality tested in PCR for specificity, sensitivity and reproducibility for specific probe/primer using
hematopoietic cell lines, blood positive and negative samples.
VI. Speed
Total reaction time is less than 2 hour.

ABL1 T315I MutIKitD

1. This Kit is intended for molecular biology applications and is not intended for the prevention or treatment of a disease.

2. All reagents may exclusively be used for in vitro diagnostics.

3. The product is to be used by personnel specially instructed and trained in for the in-vitro diagnostics procedures only.

4. It is important to pipet the indicated quantities, and mix well after each reagent addition. Check pipettes regularly.

5. Instructions must be followed correctly in order to obtain correct results.

6. This test has been validated for use with the reagents provided in the kit. The use of other Reagents or methods, or the
use of equipment not fulfilling the specifications, may render equivocal results.

7. Detection of translocation depends on the number of fusion transcripts present in the sample, and can be affected by
sample collection methods, patient-related factors (e.g. age, symptoms) or for infection stage and sample size.

8. Cross contamination between samples and exogenous DNA can only be avoided by following good laboratory practice.

9. Attention should be paid to expiration dates printed on the kit box. Do not use expired product.

ABL1 T315I MutIKitD

1. Jabbour E, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure
of imatinib mesylate therapy. Blood 2008;112:53-5.

2. Jabbour E, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine
kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood
2009;114:2037-43.

3. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl
J Med 2001;344:1031-7.

  • Free shipping
  • Best Price
  • Two years waranty on every product
  • Available on diffrent colors
  • Product Code: 52
  • Reward Points:
  • Availability: False
  • Old Price: $0
  • Ex Tax: $0.0
  • Ex Tax: $0.0
  • Product Code: 52
  • Reward Points:

Write a Review

Leave a comment

 

Comments (0)

Popular Brands See Our Popular Brands